← Eichor
Condition: Ovarian Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ovarian Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
Phase 4 · 4 location(s) · University of Miami · NCT06412120To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
NA · 1 location(s) · Yong Wha Moon · NCT07651124Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Phase 3 · 59 location(s) · GOG Foundation · NCT05659381Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Ca
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT04038619Quantum Menstrual Health Monitoring Study
Phase N/A · 1 location(s) · Quanovate Tech Inc. · NCT05936840A Study of Intra-operative Imaging in Women With Ovarian Cancer
Phase 3 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT04878094Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Phase 3 · 11 location(s) · NX Development Corp · NCT05804370A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · 58 location(s) · Eisai Inc. · NCT04300556A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Phase 1 · 21 location(s) · Bristol-Myers Squibb · NCT06997029Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Phase 1 · 1 location(s) · Monopar Therapeutics · NCT06337084A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Meth
Phase N/A · 1 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06028724Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 1/Phase 2 · 3 location(s) · Mayo Clinic · NCT05920798Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06883487Use of TDCS Stimulation in Neurological and Gynaecological Conditions
NA · 1 location(s) · Poznan University of Physical Education · NCT06891690A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/Phase 2 · 67 location(s) · AstraZeneca · NCT05123482SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Phase 1 · 5 location(s) · Verismo Therapeutics · NCT05568680Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Phase 1/Phase 2 · 60 location(s) · AstraZeneca · NCT05797168Determinants of Insulin Sensitivity by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis
Phase N/A · 1 location(s) · Ali Chappell · NCT05950282A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combi
Phase 1 · 4 location(s) · Persevere Therapeutics Inc. · NCT03854110Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Pro
NA · 1 location(s) · The First Hospital of Jilin University · NCT07495384Trop2-targeted immunoPET Imaging of Solid Tumors
Phase 2/Phase 3 · 1 location(s) · RenJi Hospital · NCT06851663Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
Phase 2 · 88 location(s) · ARCAGY/ GINECO GROUP · NCT05183984The Benefits of Continued Use of Ovarian Function Suppression After 5 Years
Phase N/A · 1 location(s) · Hongmei Zheng, PhD · NCT06050109Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
Phase N/A · 3 location(s) · University Health Network, Toronto · NCT05403177Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT07675967Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Phase 1 · 3 location(s) · BioEclipse Therapeutics · NCT04282044IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment
Phase 2 · 1 location(s) · InxMed (Shanghai) Co., Ltd. · NCT06014528Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma
Phase N/A · 10 location(s) · Azienda USL Reggio Emilia - IRCCS · NCT06749600Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.